31 Aug 2020 --- Nestlé Health Science (NHSc) has entered into a definitive agreement to acquire Aimmune Therapeutics, which is a biopharmaceutical company developing treatments for life-threatening food allergies. NHSc already has a total investment of US$473 million in Aimmune, an approximate 26 percent equity ownership stake. The value of the acquisition is estimated at US$2.6 billion and is expected to close in the fourth quarter of 2020. The move extends NHSc’s food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies, the company says.
